Our diagnostics approach

A fuller picture of
a patient’s disease

We build impactful digital pathology diagnostics to directly improve patient outcomes

Explore our solutions

Challenges

What if we could help pathologists and oncologists deliver precision medicine to their patients?

Challenge 1

Treatment burden

Treatments for cancer can be toxic, invasive, expensive and may not always be necessary or effective

Challenge 2

Disease heterogeneity

Cancer is a highly heterogeneous disease. Even cancer of one tissue can have many subtypes. Each subtype may respond to treatments differently.

Challenge 3

Anatomic pathology is underutilized

Digital pathology slides hold vast amounts of hidden insights and unlike genomic data, they are routinely generated in the clinical workflow

How can Owkin's models help enhance pathologists’ work, predict molecular phenotypes and signatures, and predict patient outcomes?

Context

Is AI the key to unlocking digital pathology’s potential?

With the advancements of machine learning, the abundance of information contained in pathology slides can be leveraged like never before.

AI solutions can support pathologists in daily tasks, prescreen for predictive biomarkers, and provide insight into patient outcomes to support treatment decision making.

Precision medicine

Not all AI tools are alike

AI-based solutions will make precision medicine more effective and accessible.

*Echie et al (Kather group), 2020, bJC

Owkin’s solution

Prescreen for biomarkers and assess patient outcomes

Owkin delivers AI diagnostics that integrate seamlessly into the digital pathology workflows to support accurate and timely diagnosis.

Giving healthcare providers a fuller picture of a patient’s disease means more patients can benefit from targeted therapies, making precision medicine more accessible to more patients at an earlier stage of their disease.

MSIntuit™ CRC RlapsRisk™ BC

Companion diagnostics

We develop digital pathology based companion diagnostics, either in house or through partnership with biopharma, to support the clinical development and market access of novel therapies.

Pre-screening for known biomarkers

Identify subgroups of patients that benefit from targeted therapies.

Novel biomarkers & outcome prediction

Match new therapies to patients and/or better characterise patients’ risk.

Build a CDx with us

What makes Owkin different?

Owkin data expertise focuses on diversity and multimodality

MSI model performance

Owkin MSIntuit CRC is the highest performing AI model in CRC on the market.¹

Academic network

Our trusted KOL network and connection to leading cancer centers in Europe/US to identify the datasets and right partners to work with.

Scientific track record

Owkin has a track record of publications in leading medical peer-reviewed journals (Nature Medicine, Hepatology, JCO etc) and societies (ESMO, ASCO, USCAP).

Recognition and grants

PortrAIt consortium funded by French Public Investment Bank to develop AI diagnostic in pathology in France in 30 centers, including the 19 expert oncology centers in France.

Affiliate consortia

Owkin consortia

Humanity

Meet the people at the heart of AI in healthcare

RlapsRisk ^™ BC

Assess the risk of breast cancer relapse.

RlapsRisk™ BC is an AI diagnostic to help pathologists and oncologists determine the right treatment pathway for early breast cancer patients.

Find out more

MSIntuit ^™ CRC

Optimize MSI testing for colorectal cancer.

MSIntuit™ CRC is a CE-marked AI diagnostic that provides a prescreen approach with digital pathology